Mole modifications following controlled ovarian stimulation for assisted reproduction technologies. 2015

M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy.

BACKGROUND The role of estrogens on moles biology remains undefined although estrogenic receptors have been found on melanocytes. It has been postulated that supraphysiological estrogen levels could promote the progression of moles to melanoma. Women undergoing controlled ovarian stimulation (COS) for assisted reproductive technologies (ART) are exposed to high levels of estrogens, produced by the ovary in response to exogenous gonadotropin administration. The aim of this study is to assess whether COS for ART may have an impact on mole structure and/or characteristics. METHODS Women undergoing to ART for various infertility conditions were included in the study. Personal and clinical data were collected. Dermatoscopic features and scores (total dermoscopy score--TDS) were statistically compared before COS and after a 6-month follow-up period. Statistical correlation was performed between estradiol, FSH blood levels and relative variation in moles dimensions. RESULTS A total of 46 patients were included in the study. One hundred and seventy-five melanocytic lesions from 31 patients were evaluated at both time points. Although statistically significant differences were found in mole dimension and TDS between the two time points, these differences had no relevance in the clinical setting not suggesting the need for mole excision. Moreover, the only statistically significant correlation with estradiol blood concentration on hCG administration day was found with one-axis dimensional variation. CONCLUSIONS To our knowledge this is the first work to evaluate the effect of COS on moles. The obtained results do not support a causal relation between the supraphysiological hormone levels stimulation and worsening of clinical and dermoscopical features of moles. Further study is needed to clarify whether estrogens plays a role in melanoma.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D009508 Nevus, Pigmented A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi. Nevus, Melanocytic,Nevi, Melanocytic,Nevi, Pigmented,Pigmented Moles,Melanocytic Nevi,Melanocytic Nevus,Pigmented Nevi,Pigmented Nevus
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D012102 Reproductive Control Agents Substances used either in the prevention or facilitation of pregnancy. Agents, Reproductive Control,Control Agents, Reproductive
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
June 1996, Current opinion in obstetrics & gynecology,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
September 2018, Fertility and sterility,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
January 1996, Andrologia,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
February 2009, Fertility and sterility,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
August 2011, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
January 2023, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
May 2000, Human reproduction (Oxford, England),
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
September 2013, Fertility and sterility,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
March 2020, Journal of assisted reproduction and genetics,
M Auriemma, and M Di Nicola, and S Varrati, and A Carbone, and A Pamio, and A Capo, and M Tracanna, and A P Castigliego, and G M Tiboni, and P Amerio
January 2001, Medicine and law,
Copied contents to your clipboard!